Medicenna Therapeutics Reports FY GAAP EPS Loss
Medicenna Therapeutics (TSX: MDNA) reported a fiscal year GAAP earnings per share loss of -C$0.22 for the period ending March 31, 2026. The company ended the year with C$6.3 million in cash and cash equivalents.
